Rivaroxaban for the treatment of venous thromboembolism in pediatric patients

Omri Cohen, Sarina Levy-Mendelovich, Walter Ageno

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Introduction: Anticoagulant therapy is in use for both prevention and treatment of venous and arterial thromboembolic disorders. Delivering safe and effective anticoagulation in the pediatric population is challenging, since the available standard therapy with parenteral UFH and LMWH is troublesome for most pediatric patients, and VKAs require frequent INR monitoring due to the unpredictable pharmacokinetics and numerous food and drug interactions. Rivaroxaban, a direct FXa inhibitor, offers the convenience of oral administration and predictable pharmacokinetics across a wide range of patients. Its safety and efficacy have been previously established in various adult indications. Areas covered: This review outlines pharmacologic and clinical aspects regarding rivaroxaban treatment in adults and children, and provides a broad appraisal of the The EINSTEIN-Jr program which evaluated the safety and efficacy of body-weight adjusted pediatric rivaroxaban regimens for the treatment of VTE in children. A review of the literature using the keywords rivaroxaban and pediatric venous thromboembolism was conducted within the National Center for Biotechnology (NCBI) and EMBASE databases. Expert opinion: Rivaroxaban represents an appealing therapeutic alternative for VTE in children. Further research should explore additional indications for rivaroxaban in the pediatric population beyond that of VTE.

Original languageEnglish
Pages (from-to)733-741
Number of pages9
JournalExpert Review of Cardiovascular Therapy
Issue number11
StatePublished - Nov 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.


  • anticoagulation
  • factor Xa
  • pediatric
  • Rivaroxaban
  • venous thromboembolism


Dive into the research topics of 'Rivaroxaban for the treatment of venous thromboembolism in pediatric patients'. Together they form a unique fingerprint.

Cite this